Coverage / AMRN / Trade Card

AMRN

Amarin Corporation PLC

OPPORTUNISTIC BUY Analysis generated 2026-10-04 Market data as of 2026-11-12 Market data 3 days old USD 11.67 Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
59

Position levels

Currenttoday
USD 11.67
Buy <=wait / entry
USD 9.33
Trim >=take some off
USD 13.00
Thesis breakThe thesis would be invalidated by termination or material restructuring of the ...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case26%100 / 10026.0
Base case49%62 / 10030.4
Bear case25%10 / 1002.5
Weighted conviction59 / 100 - OPPORTUNISTIC BUY

Top risks

  • Exclusive licensing and supply agreement with Recordati for VAZKEPA commercialization across 59 European countries including $25M upfront and up to $150M milestones
  • Supply agreement extending to 2039 with Recordati
  • Targeted $70M annual cost savings from global operations streamlining
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n